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αβ T cell receptors (TCRs) are genetically restricted to corecognize pep-
tide antigens bound to self-major histocompatibility complex (pMHC)
molecules; however, thebasis for thisMHC specificity remains unclear.
Despite the current dogma, evaluation of the TCR–pMHC-I structural
database shows that the nongermline-encoded complementarity-
determining region (CDR)-3 loops often contact the MHC-I, and
the germline-encoded CDR1 and -2 loops frequently participate in
peptide-mediated interactions. Nevertheless, different TCRs adopt
a roughly conserved docking mode over the pMHC-I, in which three
MHC-I residues (65, 69, and 155) are invariably contacted by the TCR in
one way or another. Nonetheless, the impact of mutations at these
three positions, either individually or together,was not uniformly det-
rimental to TCR recognition of pHLA-B*0801 or pHLA-B*3508. More-
over, when TCR–pMHC-I recognition was impaired, this could be
partially restored by expression of the CD8 coreceptor. The structure
of a TCR–pMHC-I complex inwhich these three (65, 69, and 155)MHC-I
positions were all mutated resulted in shifting of the TCR footprint
relative to the cognate complex and formation of compensatory inter-
actions. Collectively, our findings reveal the inherent adaptability of
the TCR in maintaining peptide recognition while accommodating
changes to the central docking site on the pMHC-I.
MHC restriction | T cell recognition | structural immunology |
immunogenetics
During thymic selection αβ T cell receptors (TCRs) are se-lected for weak reactivity with one or more self-peptides in
complex with self-MHC (major histocompatibility complex),
resulting in mature T cells being restricted to recognize pro-
cessed peptides only when they are presented by self-MHC
molecules (1). The exquisite specificity of TCR–pMHC binding
must address the highly polymorphic nature of the MHC and
variable peptide cargo. The antigen-recognition site of the TCR
is made up of six complementarity-determining regions (CDRs),
three each from the α and β chains (2). Currently, it is postulated
that the CDR1 and 2 loops underpin the specificity or “bias” to-
ward the MHC, whereas the CDR3 loops recognize the diverse
range of bound peptides (3–5). Recent studies support the view
that the T cell repertoire is intrinsically biased toward the MHC
through contacts mediated by conserved TCR Vα and Vβ residues
(6). However, the factors governing MHC restriction, a central
paradigm of antigen-specific T cell immunity, remain unclear.
Presumably as a consequence of the polymorphic pMHC land-
scape, and the inherent diversity of the responding T cell repertoire,
structural studies have shown that theTCRengages thepMHC-I and
pMHC-II surfaces in a range of different docking modes (2). Nev-
ertheless, conserved pairwise interactions between closely related
Vβ8.2+ TCRs and pMHC-II molecules were identified, leading to
the concept that there are defined interaction “motifs” or “codons”
between the Vα and/or Vβ domains of a TCR and a given MHC
allotype (3, 6–8).Central to the “interaction codon”hypothesis is that
the CDR1 and CDR2 loops contact the MHC, whereas the CDR3
loops “read-out” the peptide leading to an inherent MHC bias of
TCR recognition. Consistent with this perspective, mutations in the
germline-encoded CDR2β region within Vβ8.2+ TCRs impact neg-
atively on thymic selection reflecting a central role for these inter-
actions in MHC recognition (9). However, associated biophysical,
thermodynamic, and mutational studies have also shown that the
relative energetic contributions from the CDR loops can vary be-
tween the various TCR–pMHC systems (10, 11). Accordingly, it is
also considered that extrinsic factors, such as the CD8 coreceptor,
play a principal role in MHC restriction, which is consistent with
recent observations fromCD8−CD4−mice (12, 13). Nevertheless, in
the absence of the CD8 or CD4 coreceptor, a rough docking mode
between the TCR–pMHC is preserved, so that for pMHC-I, the Vα
and Vβ domains are positioned over the MHC α2- and α1-helices,
respectively (2), suggesting some hidden logic in TCR–pMHC-I en-
gagement. In searching for a central structural logic to TCR–pMHC-
I bias we have observed that, in all known TCR–pMHC-I structures,
theTCRmakes contact with threeMHCpositions (65, 69, and 155—
termed the “restriction triad”), suggesting that these may represent
a minimal docking framework to enable MHC-I restriction (14).
Here, we have investigated the underlying basis of TCR–MHC-
I specificity by testing the role of the restriction triad as a potential
mandate for TCR–MHC-I interaction, and our results challenge
some of the assumptions that currently shape our understanding
of this interaction.
Results
Mining the TCR–pMHC-I Structural Database. Presently, it is consid-
ered that most of the binding interface (>75%) of TCR–pMHC-I
interactions involves contact between the germline-encoded
CDR1/2 loops and the MHC and that the CDR3 loops primarily
contact the peptide (3). Accordingly, we analyzed the 18 unique
TCR–pMHC-I structures to calculate the relative contributions
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that the different CDR loops made in contacting the pMHC-I
(Table 1). Our analyses included TCRs that recognized self and
microbial peptides bound to MHC-I.
Our analyses showed that, on average, the CDR1/2 loops con-
tributed only ≈60% of the buried surface area (BSA) upon con-
tacting the MHC, indicating that the CDR3 loops, on average,
contribute ≈40% of the BSA in contacting the MHC (Fig. S1 and
Table 1). Inonly two systems (2CTCR-H2-Kb and 2CTCR-H2-Ld),
the CDR1/2 loops played a principal role (>75%) in contacting the
MHC, whereas in the other 16 TCR–pMHC-I complexes, the
CDR1/2 loops played a lesser role (<75%) in contacting theMHC.
For example, in six systems (LC13 TCR-HLA-B*0801, LC13 TCR-
HLA-B*4405, ELS4 TCR-HLA-B*3501, scBM3.3 TCR-H2-Kb,
AHIII12.2TCR-HLA-A2, andMEL5TCR-HLA-A2) theCDR1/2
loops contributed51–60%of theMHC-specific contacts, and in four
systems (A6 TCR-HLA-A2, SB27 TCR-HLA-B*3508, CF34TCR-
HLA-B*0801, and scKB5-C20 TCR-H2-Kb), the contributions
made by the CDR1/2 loops were only 50% or less, mandating
a greater role of the CDR3 loops in contacting the MHC. For ex-
ample, in the CF34 TCR-HLA-B*0801 complex, the CDR3 loops
contribute 57% of the BSA when contacting the MHC-I. Con-
versely, in relation to the CDR-peptide interactions, the CDR3
loops, on average contributed ≈70% of the BSA when contacting
the peptide. The CDR3 loops played a major role (>75%) in con-
tacting the peptide in 6 complexes (AHIII 12.2 TCR-HLA-A2, 1G4
TCR-HLA-A2, KK50.4 TCR-HLA-E, LC13 TCR-HLA-B*4405,
scKB5-C20 TCR-H2-Kb, and scBM3.3 TCR-H-2Kb), and thus in
the remaining 12 TCR–pMHC-I complexes the CDR1/2 loops
played a greater role (>25%) in contacting the peptide. For exam-
ple, in three systems (SB27 TCR-HLA-B*3508, CF34 TCR-HLA-
B*0801, and 2C TCR-H2-Kb), the contributions from the CDR1/2
loops in contacting the peptide were >40%. These observations
support the notion that the CDR3 loops can contribute notably
toward contacting theMHC, whereas the germline-encodedCDR1
and -2 loops can play an important role in contacting the peptide.
Restriction Triad. Analysis of the full TCR–pMHC-I structural
database showed that the three MHC positions, 65, 69, and 155
were virtually invariably involved in making TCR interactions
(Table S1). These three MHC-I positions exhibit limited poly-
morphism across all human HLA-Ia molecules, lending support
that they provide elements of a docking footprint (termed the
restriction triad) that underscores the TCR–pMHC-I interaction
(14). Although these three MHC-I positions are always contacted
by the TCR, the details of the interactions vary in each case with
different bonding properties and different CDR loop contacts
(15). Nevertheless it was notable that residues located in the
CDR3 loopsmake the vastmajority of contacts with the restriction
triad (Table S1).
We set out to examine the relative energetic contribution of the
residues within the restriction triad toward TCR–pMHC-I binding.
Wegenerateda seriesof single (Q65A,T69A,andQ155A)and triple
(Q65, T69, and Q155→A) alanine mutations within theMHC-I and
analyzed their effect on TCR binding using surface plasmon reso-
nance (SPR) in twodifferent systems (LC13TCR-HLA-B*0801 and
SB27 TCR-HLA-B*3508) (16, 17) (Fig. 1 and Table S2). The LC13
TCR recognizes theEBV-derived peptide FLRGRAYGL (referred
to as FLR) bound to HLA-B*0801 (18), and although the Q65A
mutation had no significant effect on binding, the Q155A and T69A
mutants resulted in a 2- to 10-fold decrease in affinity (Fig. 1A). In
addition the binding of the LC13 TCR to HLA-B*0801FLR was
completely abolished when all three restriction triad residues were
mutated toalanine (Fig. 1A).Next,we investigated the importanceof
these three MHC-I residues in the SB27 TCR interaction with the
13-mer viral peptide LPEPLPQGQLTAY (referred to as LPEP)
bound to HLA-B*3508 (14). Mutating the residues at positions 65
and 69 had no significant effect onTCRbinding affinity, whereas the
Q155A mutant reduced the affinity to 50 μM (Fig. 1B). Paradoxi-
cally, the triple alanine mutation involving the complete restriction
triad caused only a 2-fold decrease in affinity compared with wild
type (Fig.1B).Thecapacityof theSB27TCRto toleratemutationsat
these three positions was surprising, given that our earlier work had
shown that this TCR made limited contacts with HLA-B*3508 in-
cluding the threepositions (65, 69, and155) that represent conserved
contact points in the TCR–pMHC-I interaction.
T Cell Activation. We next investigated the effect of these restric-
tion triad mutations on T cell activation. We analyzed CD69 up-
Table 1. Relative contribution of the complementarity determining regions (CDR loops) to the binding of the MHC helices and the
peptide
% total BSA of TCR-MHC interaction % total BSA of TCR-peptide interaction
PDB MHC Peptide TCR CDR1α CDR2α CDR3α CDR1β CDR2β CDR3β CDR1α CDR2α CDR3α CDR1β CDR2β CDR3β
1AO7 HLA-A2 LLFGYPVYV A6 35 14 25 0 0 26 28 0 21 5 0 46
1BD2 HLA-A2 LLFGYPVYV B7 30 23 21 0 13 13 27 0 18 2 0 53
2BNR HLA-A2 SSLMWITQC 1G4 4 19 24 11 30 12 14 0 36 10 0 40
3GSN HLA-A2 NLVPMVATV RA14 17 13 17 6 20 27 39 0 20 7 0 34
1LP9 HLA-A2 ALWGFFPVL AHIII 12.2* 22 13 26 6 14 19 0 0 50 9 1 40
3HG1 HLA-A2 ELAGIGLTV MEL5 21 15 19 5 14 26 25 7 8 0 0 60
1MI5 HLA-B*0801 FLRGRAYGL LC13 16 18 23 3 21 19 23 4 27 0 0 46
1OGA HLA-A2 GILGFVFTL JM22 11 10 10 3 39 27 11 28 31 0 0 30
2AK4 HLA-B*3508 LPEPLPQGQLTAY SB27 13 9 39 0 9 30 4 0 39 42 3 12
2ESV HLA-E VMAPRTLIL KK50.4 20 5 19 3 36 17 6 0 45 8 11 30
2NX5 HLA-B*3501 EPLPQGQLTAY ELS4 12 16 22 15 16 19 5 0 21 27 0 47
3DXA HLA-B*4405 EENLLDFVRF DM1 25 19 21 5 19 11 16 1 33 11 0 39
3KPS HLA-B*4405 EEYLQAFTY LC13 16 14 22 5 21 22 22 0 30 0 0 48
3FFC HLA-B*0801 FLRGRAYGL CF34 16 13 19 1 13 38 0 0 18 18 23 41
2CKB H-2Kb EQYKFYSV 2C 24 17 15 13 22 9 26 0 25 33 7 9
2OI9 H-2Ld QLSPFPFDL 2C 19 27 15 10 25 4 19 0 18 24 9 30
1KJ2 H-2Kb KVITFIDL scKB5-C20 8 13 30 17 12 20 7 0 38 8 10 37
1NAM H-2Kb RGYVYQGL scBM3.3 17 13 24 29 0 17 6 0 30 0 0 64
Average 18 15 22 7 18 20 16 2 30 12 4 41
BSA was calculated with the PDBePISA Web site, www.ebi.ac.uk.
*AHIII12.2 is a mouse TCR, xenoreactive complex.
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regulation on the Jurkat cell line, transfected with either the LC13
TCR (19) or the LC13 TCR and CD8, following stimulation with
antigen-presenting cells treated with various concentrations of the
FLRGRAYGL peptide. Stimulator cells were transfected deriv-
atives of the antigen-processing mutant T2 cell line expressing
wild-type and mutant HLA-B*0801. The mutants contained ala-
nine substitutions at position 65, 69, or 155, or at all three of these
positions. Surface expression of mutant HLA-B*0801 molecules
was assessed by overnight peptide-stabilization assays, and cells
were matched for MHC-I surface expression such that the T2
transfectants expressing HLA-B8 and its mutants were equivalent
in their surface expression.
For the LC13 activation, the Q65A mutation had no significant
effect onCD69up-regulation, regardless ofwhetherCD8was present
(Fig. 1C). T cell activation was impaired with the T69A and Q155A
mutants (T69A > Q155A) and interestingly, the presence of CD8
substantially rescuedtheabilityof theLC13TCRtoup-regulateCD69
when stimulatedby theT69AorQ155Amutants ofHLA-B*0801FLR.
Similarly, when all three restriction triad residues were mutated to
alanine, T cell activation was dramatically reduced, and the presence
of CD8 only partially rescued T cell activation (Fig. 1D). Accordingly,
as judged by SPR and CD69 up-regulation, the LC13 TCR-HLA-
B*0801FLR interactionwas dependent ononeormore residueswithin
the restriction triad; nevertheless, the impact of these restriction triad
mutations was partially rescued by the CD8 coreceptor.
Cytotoxicity Assays. To examine whether the restriction triad is re-
quired for T cell cytotoxicity, we performed chromium-release assays
withapanelof independentHLA-B*0801-orHLA-B*3508-restricted
T cell clones from different individuals and targeted to different
epitopes. Firstly, we examined CTL recognition of HLA-B*0801FLR
by12differentT cell clones, aswell as twoCTLclones directed against
the HLA-B*0801-restricted RAKFKQLL (referred to as RAK) epi-
tope (20). Secondly, we examined the effect of the mutations on
a number of clones targeted to one of four HLA-B*3508-restricted
viral epitopes of different length: a 13-mer (LPEPLPQGQLTAY),
a 12-mer (CPSQEPMSIYVY), an 11-mer (HPVGEADYFEY), or
a 10-mer (APQPAPENAY) (21–24).
Consistent with the SPR and CD69 up-regulation assays, lysis by
theLC13CTL clonewas greatly inhibited by theT69A,Q155A, and
the triple restriction triad mutations (Fig. 2A). Moreover, six other
HLA-B*0801FLR-restricted CTL clones (SBD11, PP36, SBD12,
RL29,BK10, andRL16) exhibitedmarkedlydiminishedCTLkilling
when either one or all of the restriction triad residues weremutated
to alanine (loss-of-function hierarchy triple Ala > 155 > 69). No-
tably however, some CTL clones displayed much less dependency
on the residues comprising the restriction triad, even to the point
that CTL killing of target cells expressing the triple Ala restriction
triad mutant of HLA-B*0801FLR still occurred for five CTL clones
(JL9, CFA27, GL3, CFB40, andCFB14). To test whether this latter
observation was peculiar to the HLA-B*0801FLR epitope, we also
examined CTL recognition of the HLA-B*0801RAK determinant.
One CTL clone (LC9) was shown to be dependent upon the re-
striction triad (triple Ala or 155 > 69 > 65), whereas cell lysis by
another CTL clone (LC1) was only modestly impacted by single
mutations and unaffected by the triple Ala mutations within the
restriction triad (155 ≥ 65, Fig. 2B).
Just as the SPR data showed that the SB27 TCR could still
bind well to the triple Ala restriction triad mutant of HLA-
B*3508LPEP, SB27 CTL killing of APC-expressing triad muta-
tions was indistinguishable from killing of wild-type cells. Addi-
tionally, two other CTL clones specific for this 13-mer peptide
(SB9 and CA5) with different TCRs (14, 16, 23) were insensitive
to the restriction triad mutations (Fig. S2). Similarly, some CTL
clones directed against the 12-mer, 11-mer, and 10-mer peptides
could tolerate mutations in the restriction triad. However, de-
pendency on the triad residues was notable in some of the CTL
clones (SB10, SB14, SB8, and SB16) that were targeted toward
Fig. 1. The role of the “restriction triad” residues in TCR–pMHC-I binding as
judged by SPR analysis and CD69 up-regulation. (A) Equilibrium binding of the
LC13TCRtoHLA-B*0801FLR (WT),ormutantHLA-B*0801FLRwithaQ65A,aT69A,
or a Q155A substitution, or the triple restriction triadmutant of HLA-B*0801FLR.
(B) Equilibriumbindingof theSB27TCR toHLA-B*3508LPEP (WT), ormutantHLA-
B*3508LPEPwith aQ65A, a T69A, or aQ155A substitution,or the triple restriction
triad mutant of HLA-B*3508LPEP. Data are representative of at least four in-
dependent experiments. (C) CD69 up-regulation within Jurkat cells transfected
with the LC13 TCR or (D) the LC13 TCR and CD8. The experiments were con-
ducted at least twice with similar results.
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the shorter HLA-B*3508-restricted epitopes and that were par-
ticularly sensitive to mutation of residue 155 (Fig. S2 B–D).
Accordingly, against the panel of 24 CTL clones, there was
large variation in the dependency on the restriction triad in en-
abling CTL killing.
Compensatory Interactions. We aimed to gain an understanding of
how a TCR could tolerate mutations in the three restriction triad
MHC-I-contacts points. We reasoned that the SB27 TCR-HLA-
B*3508LPEP complex would represent an ideal system to in-
vestigate this, as the SB27 TCR made limited contacts with the
cognateHLA-B*3508—namely, interactingwith only two residues
on the α1-helix (65 and 69) and a focused series of contacts on the
α2-helix (150-151, 154-155, 157-159, and 163) (14). Accordingly,
we solved the structure of the SB27TCRbound toHLA-B*3508 in
which the restriction triadswere allmutated to alanine (referred to
as HLA-B*3508-AAALPEP) (Table S3). We also solved the struc-
ture of HLA-B*3508-AAALPEP in the nonliganded state to 2.2 Å
resolution (Table S3) to ascertainwhether themutations impacted
on conformation of the peptide within the Ag-binding cleft.
The HLA-B*3508-AAALPEP structure and the wild-type HLA-
B*3508LPEP structure (16) were very similar, indicating that the
restriction triad mutation does not affect the conformation of the
bound peptide. Similar to the SB27 TCR-HLA-B*3508LPEP
complex, the SB27 TCR perched atop the bulged peptide of the
HLA-B*3508-AAALPEP complex. However the SB27 TCR-HLA-
B*3508-AAALPEP complex shifted 8° with respect to how the
SB27 TCR docked onto HLA-B*3508LPEP (see SI Materials and
Methods), resulting in the SB27 TCR tilting more toward the α2-
helix when bound toHLA-B*3508-AAALPEP (Fig. 3A) (Table S4).
The SB27 TCR made very few contacts with the MHC helices of
HLA-B*3508-AAALPEP, with only 3 direct hydrogen bonds and
two salt bridges being made exclusively with residues on the α2-
helix (Fig. 3B). Although a number of van derWaal (vdw) contacts
were made with the α2-helix, the interactions with the α1-helix
were limited to one vdw contact with Arg-62. In comparison with
the SB27 TCR-HLA-B*3508LPEP complex, in the HLA-B*3508-
AAALPEP complex SB27 loses two direct hydrogen bonds to Gln-
65 andGln-155, and two vdw interactionswith residuesGln-65 and
Thr-69. However, these interactions are compensated in this
complex, by additional H-bonds toGlu-166 and toAla-158, as well
as vdw interactions with Arg-62, Ala-149, Glu-161, and Gly-162
(Fig. 3 B and C). Consequently, when compared with the SB27
TCR-HLA-B*3508LPEP complex, the SB27 TCR buries an addi-
tional ≈150 Å2 when binding to the HLA-B*3508-AAALPEP.
Collectively, this demonstrates how the SB27 TCR can adapt
to productively engage a pMHC-I ligand in the absence of the
restriction triad residues of HLA-B*3508.
Discussion
The germline-encoded V genes of the TCR are thought to de-
termine bias toward the MHC (4, 5), and consistent with this view
there is evidence for preserved “interaction motifs” between the V-
gene encoded regions of a TCR and a givenMHC-II allotype (6, 7).
This has only been reported within a narrow slice of the Vβ reper-
toire, where consensus Vβ8.2+ CDR2β-mediated interactions were
observed with closely related pMHC-II molecules (6, 7). It is also
suggested that the same V region can potentially interact with dis-
Fig. 2. The impact ofmutation atMHC α-helix positions 65, 69, and/or 155 on recognition by HLA-B*0801-restricted CTL clones. The antigen-processingmutant
T2 cell line was used as a target in chromium-release cytotoxicity assays, either without transfection (see vertical axis: No HLA-B*0801) or transfected to express
wild-type HLA-B*0801 (WT HLA-B*0801), or mutant HLA-B*0801molecules with alanine substitution at position 65, 69, or 155, or at all three of these positions.
These target cells were treated for 1 h with various concentrations (10−6 M, 10−7 M, 10−8 M, 10−9 M, and 10−10 M) of the HLA-B*0801-restricted EBV peptides
FLRGRAYGL (A) or RAKFKQLL (B), and washed before CTL addition. CTL clones specific for each of these peptides were used as effectors (E:T = 1:1), and the
concentrationofpeptide required for halfmaximal lysiswas calculated fromthedose–response curves. (A) TheFLRGRAYGL-specific CTL cloneswere LC13 (34, 35),
JL9, SBD11, CFA27, PP36, SBD12, GL3, RL29, CFB40 (34), CFB14, BK10 (36), and RL16 (34, 37). These experiments were independently performed twice for clones
LC13, GL3, and CFB40, with analogous results on each occasion. Furthermore, the CFB34 CTL clone, which shares an identical TCRwith CFB40, gave similar results
to those shown for CFB40. The other clones were tested in a single experiment, using duplicate samples. (B) The RAKFKQLL-specific CTL clones were LC9 and LC1,
which have not been described previously. These clones were tested in a single experiment, using duplicate samples.
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parate pMHCmolecules in a different register (3), as exemplifiedby
the divergent docking modes of the Vβ8.2 2C TCRwith H2-Kb and
H2-Ld (25, 26). Further, given the influence of the peptide-TCR
contacts in any given TCR–pMHC system, the binding energy
contributed by the interaction motif can be critically supplemented
to enable the TCR to bind in another “MHC register” (3, 27). Ac-
cordingly, the proposed role of interaction codons or motifs occurs
on a backdrop of considerable “noise” in relation to the generality
and exclusivity of their function in defining the TCR–pMHC ori-
entation. Collective structural analyses raise additional questions
about thegeneralization that theCDR1/2 loopsdictateMHC-Ibias.
Namely, the current TCR–pMHC-I structural database demon-
strates that the germline-encoded CDR1/2 loops frequently play an
important role in contacting the peptide, but perhaps more criti-
cally, the CDR3 loops can and do play a principal role in contacting
theMHC-I. This interpretation is further supported bymutagenesis
experiments that demonstrated an important energetic role for the
CDR3 loops in contacting theMHC-I and for the CDR1/2 loops in
contacting the peptide (8, 11).
Whereas theTCR-MHCcontacts are typically extensive, binding
studies have shown that these interactions are governed by “ener-
getic hotspots” (10, 11). Consistent with this finding, our analyses
showed that three (65, 69, and 155) positions, on the MHC were
invariably contacted in essentially all TCR–pMHC-I systems
reported to date (14). Accordingly, we set out to establish whether
these three positions represented the minimal docking framework
required to enable MHC-I restriction in two HLA families, which
differ from each other by 19 amino acids. Surprisingly, the de-
pendency of the restriction triad varied among the different CTL
clones examined. For example, whereas the LC13 TCR-HLA-
B*0801FLR interaction was wholly dependent on the restriction
triad, 5 of another 12CTL clones targeted towardHLA-B*0801FLR
tolerated mutations of the restriction triad. Similarly, the HLA
B*3508-restricted CTL clones recognizing the 10-mer, 11-mer, and
12-mer peptides exhibited varied dependency on the restriction
triad. However, all three CTL clones that recognize the HLA-
B*3508LPEP complexwere somewhat independent of the restriction
triad. The latter finding suggests that the peptide-centric recogni-
tionofCTLclones that recognize lengthypeptides couldpotentially
outweigh any energetic contribution by theHLA-B*3508molecule.
The structure of the SB27 TCR ligated to HLA-B*3508-
AAALPEP showed how the SB27 TCR retained specificity for this
alteredpMHC-I landscape.Namely, the slippage of the SB27TCR
footprint enabled compensating interactions to be made with the
MHC-I, simultaneously highlighting the inherent cross-reactivity
of TCRs in interacting with different MHC ligands during allor-
esponses. These observations are consistent with other evidence
that the TCR is finely tuned to alterations in the peptide Ag, yet
remarkably tolerant to alterations in the MHC (28). It is con-
ceivable that the energetic contributions from the restriction triad
residues play a more consistent and critical role in TCR binding to
weak affinity ligands during thymic positive selection. The impact
of this dependency could then persist to a variable degree in ma-
ture T cells selected by specific antigenic peptides.
Whereas the αβ T cell repertoire is vast, many virus-specific
immune responses are characterized by biased TCR usage (29,
30). Nevertheless, biases in the overall peripheral Vβ repertoire
between unrelated individuals who share the same HLA alleles
are rare (31), which argues against a general role for preferential
pairwise TCR-MHC interaction motifs. Perhaps this is partly
explained by the complexity of repertoire selection against up to
12 distinct MHC allotypes (assuming 6 heterozygous loci); how-
ever, one might still expect a general bias in Vβ selection across
specific MHC allotypes and this has only been evident in twin
studies (31). On the other hand, repeated selection of particular
V regions and/or D/J and N-region genetic elements in antigen-
specific responses indicates that these regions must encode ex-
quisite interactions to enable TCR interaction with self-MHC
complexed to specific peptides (30, 32). It is notable that, in the
examples where TCRs that exhibit biased gene usage have been
examined structurally (32), germline-encoded regions can often
play a central role in interacting with the peptide determinant
(Table 1). The evolution of the TCR V/D/J genes has undoubt-
edly been driven by infection by pathogens and in particular, the
requirement to respond rapidly to viral peptides. It is therefore
not unexpected that the CDR1/2 germline-encoded regions of the
TCR might also frequently bind peptide as well as the presenting
MHC-I molecule and that biased TCR V-gene use has frequently
been described for particular pMHC complexes but rarely for
particular MHC allotypes.
Hence, the TCR bias for binding to pMHC molecules is built
on a suite of hard-wired interactions between the TCR and
conserved MHC residues at positions 65, 69, and 155. None-
theless, the clonal dependence upon these interactions can vary
in the mature T cell repertoire such that TCR flexibility can still
underpin MHC-recognition by substituting new compensatory
contacts. We conclude that the conundrum of how TCRs restrict
their interactions to pMHC (and MHC-like) molecules and not
other molecular surfaces is surprisingly subtle.
Materials and Methods
Mining of the TCR–pMHC-I Database. There are currently 33 TCR–pMHC-I
structures in the Protein Data Bank database, which includes a series of very
closely related TCR–pMHC-I complexes. Accordingly, one representative
TCR–pMHC-I from each of these systems was used in the analysis, which
amounted to 18 nonredundant TCR–pMHC-I complexes. The BSA interfaces
for each TCR–pMHC-I complex was determined using PISA and, for verifi-
cation, the BSA was also determined using AREAIMOL from the CCP4 pro-
gram suite. Both PISA and AREAIMOL gave comparable results.
Protein Production and Crystallization. The HLA-B*3508-AAALPEP and the SB27
TCR were expressed and purified and crystallized essentially as previously
described (14, 33).
Data Collection, Structure Determination, and Refinement. Data were collected
using an in-house radiation source and/or the Industrial Macromolecular
Crystallography Association–Collaborative Access Team beamline at the
Argonne Photon Source Synchrotron in Chicago and/or at the MX2 beamline
at the Australian Synchrotron. Data were processed using standard crystal-
Fig. 3. The SB27 TCR compensates for mutations in the MHC via “slippage”
of the TCR footprint on the MHC. (A) Superposition of SB27 TCR on WT MHC
(orange) compared with the position of the TCR on the “restriction triad
triple mutant” MHC (cyan). (B) Contacts made by the SB27 TCR to HLA-
B*3508-AAALPEP. The LPEP peptide is shown in dark gray; H bonds are shown
as dashed black lines; salt bridges are shown as dashed red lines. (C) Contacts
made by the SB27 TCR to the WT HLA-B*3508LPEP. CDR1α, -2α, -3α, and -3β
are colored purple, green, yellow, and orange, respectively.
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lographic software packages (Table S3). The structure of HLA-B*3508-
AAALPEP was determined by molecular replacement using the HLA-
B*3508LPEP structure as the search model (16). For the SB27-HLA-B*3508-
AAALPEP complex, the crystals belonged to the space group P21 with four
complexes in the asymmetric unit. The structure was using the SB27-HLA-
B*3508LPEP complex as the search model. For both structures, subsequent
model building was conducted using the COOT software followed by max-
imum-likelihood refinement (CCP4 suite). All structures were validated using
standard software packages.
Surface Plasmon Resonance Measurement and Analysis. All surface plasmon
resonance experiments were conducted at 25 °C on the BIAcore 3000 es-
sentially as previously described (11). All experiments were conducted in
duplicate or quadruplicate.
T Cell Activation Assay. Ag presenting cells (T2-B*0801 or T2-B*3508 trans-
fectant cells, 105/well) were cultured with peptide FLR or LPEP at the indicated
concentration in 100 μL of AimV serum free-medium overnight at 26 °C for
stablizationofpMHC-I surfaceexpression. Jurkat.LC13or Jurkat.CD8.LC13 (105/
well) were added and cocultured for 4 h at 37 °C. The cells were then pelleted
and assayed for CD69 up-regulation by staining and fluorescence-activated
cell sorting. T cell activation was measured by the increase of the mean chan-
nel fluorescence in CD69 staining of the gated GFP positive Jurkat cells.
Cytotoxicity Assays. CTL clones (Table S5) were tested in duplicate for cyto-
toxicity in a standard 5-h chromium-release assay. CTLs were assayed against
51Cr-labeled target cells at an effector:target ratio of 1:1. The target cells were
the antigen-processing mutant T2 cell line, either without transfection or
transfected to express either wild-type HLA-B*0801, or B*3508, or mutant
HLA-B*0801/B*3508molecules with alanine substitution at position 65, 69, or
155, or at all three of these positions. These target cells were treated for 1 h
with various concentrations of HLA-B*0801/B*3508-restricted viral peptide
epitopes and washed three times before CTL addition. Percent-specific lysis
was calculated, and the concentration of peptide required for half maximal
lysis was determined from the dose–response curves. Peptides were synthe-
sized byMimotopes. Themean spontaneous lysis for target cells in the culture
medium was always <20%, and the variation about the mean-specific lysis
was <10%.
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Database Mining and Structural Analyses. TCR–pMHC-I complexes
that were similar to other TCR–pMHC-I structures in the data-
base were excluded so as not to bias the analyses toward specific
TCR–pMHC-I complexes. Namely, there are five structures in-
volving theA6TCRbound toHLA-A2 presenting the Tax peptide
(or a mutant of the Tax peptide) (pdb codes: 1A07, 1QRN, 1QSE,
1QSF, and 2GJ6 (1–6), four structures of the 1G4 TCR bound to
HLA-A2 presenting variations of the NY-ESO peptide (pdb co-
des: 2BNQ, 2BNR, 2F54, and 2F53), four structures of the JM22
TCRbound toHLA-A2 (7, 8) presenting a flu peptide (pdb codes:
1OGA, 2VLK, 2VLK, and 2VLR), four structures of the 2C TCR
bound to H-2Kb or H-2Kbm3 (which only differ by four residues)
that are extremely similar in their binding (pdb codes: 1G6R,
2CKB, 1JTR, and 1MWA) (9–11), two structures of the 2C TCR
bound toH-2Ld presenting theQL9 peptide (pdb codes: 2O19 and
2E7L) (12), and finally, there are three structures of the BM3.3
TCR bound to H-2Kb or H-2Kbm8 (pdb codes: 1FO0, 1NAM, and
2OL3) (13).
Consequently, 18 unique TCR–pMHC-I complexes (5, 8, 12–27)
were analyzed and the percentage of the total buried surface area
(BSA) that each CDR loop contributed toward theTCR-MHCand
TCR-peptide interactions was determined. With respect to the
SB27 TCR-HLA B*3508 complex (20), two distinct docking ori-
entations (complexes A and B) were observed in the asymmetric
unit. The SB27 TCR-HLA-B*3508AAA complex was analyzed
against complex A and was observed to sit within the “middle” of
both complex A and complex B.
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Fig. S1. Footprints of the 18 unique TCR–pMHC-I complexes highlighting the contacts made by each CDR loop to binding the peptide and/or MHC heavy
chain. A surface representation of the MHC molecule is colored in light gray, with the bound peptide shown in sticks and colored dark gray. The residues on the
pMHC contacted by the CDR loops of each TCR are colored as follows: CDR1α, purple; CDR2α, green; CDR3α, yellow; CDR1β, blue; CDR2β, red; and CDR3β,
orange. The germline-encoded CDR1/2 loops are shown to play an important role in contacting the peptide, and the CDR3 loops (yellow and orange) con-
tribute substantially to contacting the MHC. This highlights a change in the current dogma that the CDR1/2 loops are primarily responsible for MHC bias.
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Fig. S2. The impact of mutation at MHC α-helix positions 65, 69, and/or 155 on recognition by HLA-B*3508-restricted CTL clones. Chromium-release cyto-
toxicity assays were performed as described in the legend for Fig. 3. Target cells were T2 cells either without transfection (see vertical axis: No HLA-B*3508) or
transfected to express wild-type HLA-B*3508 (WT HLA-B*3508), or mutant HLA-B*3508 molecules with alanine substitution at position 65, 69, or 155, or at all
three of these positions. These target cells were treated for 1 h with various concentrations (10−7 M, 10−8 M, 10−9 M, 10−10 M, 10−11 M, and 10−12 M) of the
HLA-B*3508-restricted EBV or HCMV peptides LPEPLPQGQLTAY (28, 29) (A), CPSQEPMSIYVY (30) (B), HPVGEADYFEY (31) (C), or APQPAPENAY (32) (D), and
washed before CTL addition. CTL clones specific for each of these peptides were used as effectors (E:T = 1:1), and the concentration of peptide required for half
maximal lysis was calculated from the dose–response curves. (A) The LPEPLPQGQLTAY-specific CTL clones were SB27 (20, 29), SB9 and CA5 (29). These ex-
periments were independently performed twice for each of these clones, with analogous results on each occasion. Furthermore, the SB27 CTL clone was also
tested for recognition of these peptide-treated target cells using an IFN-γ Elispot assay, and very similar results to those shown in the figure for SB27 were
observed (data not shown). (B) The CPSQEPMSIYVY-specific CTL clone was SB10 (33). (C) The HPVGEADYFEY-specific CTL clones were SB4 (31), SB24, and MB4
(31). (D) The APQPAPENAY-specific CTL clones were SB7, SB8, and SB16 (32). The CTL clones shown in B, C, and D were tested in a single experiment, using
duplicate samples.
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Table S2. Surface plasmon resonance measurements of the SB27 and LC13 TCRs with their
wild-type and alanine mutant pMHC ligands
Analyte (pMHC) TCR Kd (μM) Result
HLA-B*0801 wild type LC13 10.4 Wild type
HLA-B*0801 Q65A LC13 9.7 No effect
HLA-B*0801 T69A LC13 >100 10× decrease
HLA-B*0801 Q155A LC13 18.8 2× decrease
HLA-B*0801 triple Ala (65_69_155) LC13 No binding at 350 μM No binding
HLA-B*3508 wild type SB27 11.2 Wild type
HLA-B*3508 Q65A SB27 8.6 No effect
HLA-B*3508 T69A SB27 8.8 No effect
HLA-B*3508 Q155A SB27 50 5× decrease
HLA-B*3508 Triple Ala (65_69_155) SB27 27 2.5× decrease
Table S3. Data collection and refinement statistics
HLA-B*3508_AAALPEP SB27- HLA-B*3508_AAALPEP
Data collection
X-ray source Australian Synchrotron Australian Synchrotron
Space group P212121 P 21
Cell dimensions
a, b, c (Å) 51.0, 81.5, 110.4 78.7, 207.1, 123.5
α, β, γ (°) 90, 90, 90 90, 90.2, 90
Resolution (Å) 34–2.2 80–3.1
Rmerge 5.7 (29.6)
† 9.6 (34.1)†
I/σI 16.7 (3.8) 14.1 (4.1)
Completeness (%) 99.4 (99.9) 98.8 (99.3)
Multiplicity 3.3 5.1
Refinement
Resolution (Å) 34–2.18† 80–3.1
No. reflections 23559 71533
Rwork/Rfree 18.6/25.1 21.3/29.1
No. atoms
Protein 3,276 26,926
Ligand/ion 90 24
Water 348 42
B-factors
Protein 21.8 38.1
Ligand/ion 44.9 83.0
Water 34.7 14.6
Ramachandran (molprobity)
Favored (%) 97.7 92.9
Allowed (%) 100 99.2
R.m.s. deviations
Bond lengths (Å) 0.007 0.006
Bond angles (°) 1.040 1.002
†Values in parentheses are for highest-resolution shell. The values in parentheses refer to values for the rows of
Rmerge, I/σI, and completeness.
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Table S4. SB27–HLA-B*3508-AAALPEP interactions
TCR residue MHC residue Bond type Gene segment
CDR1α Thr-29OG1 Glu-166Oε2 H bond** Vα
CDR1α Thr-29 Glu-161, Gly-162, Glu-166 van der Waals Vα
CDR1α Thr-30OG1 Ala-158O H bond** Vα
CDR1α Thr-30 Ala-158, Glu-161, Gly-162 van der Waals Vα
FW Arg-49 Glu-154 Salt bridge Vα
CDR2α Asn-50 Glu-154, van der Waals Vα
CDR2α Asn-50NH2 Glu-154Oε2 H bond Vα
CDR2α Phe-52 Glu-154, Arg-157, Ala-158, Glu-161 van der Waals Vα
CDR3α Phe-95 Glu-154, Ala-155, Ala-158 van der Waals N region
CDR3α Tyr-96 Ala-158, Tyr-159, Leu-163 van der Waals Jα
CDR3α Thr-99 Arg-62 van der Waals** Jα
CDR3β Leu-98 Ala-150, Arg-151, Ala-155 van der Waals Vβ
CDR3β Ala-99 Ala-149, Ala-150, Arg-151 van der Waals Dβ-N
CDR3β Glu-101Oε1 Arg-151NH1 Salt bridge N-Jβ
CDR3β Tyr-102 Ala-149 van der Waals** Jβ
TCR residue Peptide residue Bond type Gene segment
CDR1α Tyr-31 Gln-7 van der Waals Vα
CDR1α Tyr-31OH Gln-7Oε1 H bond Vα
CDR3α Ser-93 Gln-7 van der Waals Vα
CDR3α Ser-93OG Gln-7Nε2 H bond Vα
CDR3α Gly-94 Gln-7 van der Waals N region
CDR3α Phe-95 Leu-5, Pro-6, Gln-7 van der Waals N region
CDR3α Tyr-96 Pro-4, Leu-5, Pro-6, Gln-7 van der Waals Jα
CDR3α Asn-97N Leu-5° H bond Jα
CDR3α Asn-97ND2 Pro-6° H bond Jα
CDR3α Asn-97 Leu-5, Pro-6, Gln-7 van der Waals Jα
CDR3α Asp-102 Gln-7 van der Waals Jα
CDR1β Met-27 Gln-9 van der Waals Vβ
CDR1β Asn-28 Gln-7, Gly-8, Gln-9 van der Waals Vβ
CDR1β His-29 Gln-7, Gly-8, Gln-9 van der Waals Vβ
CDR1β Asn-30 Pro-6, Gln-7, Gly-8, Gln-9, Leu-10 van der Waals Vβ
CDR1β Asn-30ND2 Gly-8° H bond Vβ
CDR1β Asn-30N Gly-8° H bond Vβ
CDR1β Ser-31 Pro-6, Gln-7 van der Waals Vβ
CDR1β Ser-31N Gln-7° H bond Vβ
CDR1β Tyr-33 Gln-7 van der Waals Vβ
CDR3β Pro-95 Gln-7, Gly-8 van der Waals Dβ-N
Subscripted designations indicate the atom involved in hydrogen bonding.
FW, Framework residue; H bond, hydrogen bond; V, variable; N, nongermline encoded; D, diversity; J, joining
van der Waals cutoff distance ≤4 Å.
**New contact compared with the wild-type SB27-HLA-B*3508LPEP structure (19).
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Table S5. CTL clones used in this study
CTL clone HLA restriction Peptide (and virus) specificity TCR use
LC13 HLA-B*0801 FLRGRAYGL (EBV) TRAV26-2*01; TRAJ52*01; TRBV7-8*03; TRBJ2-7*01
JL9 HLA-B*0801 FLRGRAYGL (EBV) TRAV1-2*01; TRAJ36*01; TRBV4-3*01; TRBJ2-5*01
SBD11 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized
CFA27 HLA-B*0801 FLRGRAYGL (EBV) TRBV11-2 mAb-positive
PP36 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized
SBD12 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized
GL3 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized
RL29 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized but TRBV11-2 mAb-negative
CFB40 HLA-B*0801 FLRGRAYGL (EBV) TRAV14*01; TRAJ49; TRBV11-2*03; TRBJ2-3
CFB14 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized
BK10 HLA-B*0801 FLRGRAYGL (EBV) Uncharacterized
RL16 HLA-B*0801 FLRGRAYGL (EBV) TRAV39, TRBV4-1; TRBJ2-7
LC9 HLA-B*0801 RAKFKQLL (EBV) Uncharacterized
LC1 HLA-B*0801 RAKFKQLL (EBV) Uncharacterized
SB27 HLA-B*3508 LPEPLPQGQLTAY (EBV) TRAV19; TRAJ34; TRBV6-1; TRBJ2-7
SB9 HLA-B*3508 LPEPLPQGQLTAY (EBV) TRAV19; TRAJ34; TRBV7-2; TRBJ1-5
CA5 HLA-B*3508 LPEPLPQGQLTAY (EBV) TRAV19; TRAJ34; TRBV6-1; TRBJ1-1
SB10 HLA-B*3508 CPSQEPMSIYVY (HCMV) TRAV8-6*02; TRAJ30*01; TRBV28*01; TRBJ2-7*01
SB14 HLA-B*3508 HPVGEADYFEY (EBV) TRAV3; TRAJ8; TRBV5-1; TRBJ2-5
SB24 HLA-B*3508 HPVGEADYFEY (EBV) Uncharacterized
MB4 HLA-B*3508 HPVGEADYFEY (EBV) TRAV29; TRAJ40; TRBV9; TRBJ2-2
SB7 HLA-B*3508 APQPAPENAY (EBV) Uncharacterized
SB8 HLA-B*3508 APQPAPENAY (EBV) Uncharacterized†
SB16 HLA-B*3508 APQPAPENAY (EBV) Uncharacterized†
†CTL clones SB8 and SB16 showed different specificity patterns for peptide variants, indicating they express different TCRs (18).
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